Literature DB >> 3216215

The ontogeny of 3,4-dihydroxyphenylacetic acid in human cerebrospinal fluid.

G M Anderson1, M A Riddle, E L Hoder, F C Feibel, B A Shaywitz, D J Cohen.   

Abstract

Measurement of cerebrospinal fluid (CSF) levels of the minor dopamine metabolite 3,4-dihydroxyphenylacetic acid in neonates and children indicates that a rapid decline (approximately 90%) occurs in the first 2 years of life. The much less rapid ontogenetic decline seen for the predominant dopamine metabolite, homovanillic acid (HVA), indicates that differing factors affect CSF levels of the two acid metabolites. Further study is required to determine which compound more closely reflects ontogenetic changes in dopamine functioning.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3216215      PMCID： PMC1033125          DOI： 10.1136/jnnp.51.8.1100

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  13 in total

1.  Cerebrospinal fluid neurotransmitter metabolites in neurologically normal infants and children.

Authors:  P J Langlais; F X Walsh; E D Bird; H L Levy
Journal:  Pediatrics       Date:  1985-03       Impact factor: 7.124

2.  5-hydroxyindoles in hydrocephalus. A comparative study of cerebrospinal fluid and blood levels.

Authors:  K J Rogers; V Dubowitz
Journal:  Dev Med Child Neurol       Date:  1970-08       Impact factor: 5.449

3.  Spontaneous and drug-induced changes of cerebral dopamine turnover during postnatal development of rats.

Authors:  H H Keller; G Bartholini; A Pletscher
Journal:  Brain Res       Date:  1973-12-21       Impact factor: 3.252

4.  5-hydroxyindoleacetic acid in cerebrospinal fluid of hydrocephalic children.

Authors:  H Andersson; B E Roos
Journal:  Acta Paediatr Scand       Date:  1969-11

5.  Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.

Authors:  Y Nomura; T Komori; S Okuda; T Segawa
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-01

6.  Ontogeny of dopamine and serotonin metabolites in the cerebrospinal fluid of children with neurological disorders.

Authors:  B A Shaywitz; D J Cohen; J F Leckman; J G Young; M B Bowers
Journal:  Dev Med Child Neurol       Date:  1980-12       Impact factor: 5.449

7.  Cerebrospinal fluid monoamine precursor and metabolite levels in children treated for leukemia: age and sex effects and individual variability.

Authors:  M A Riddle; G M Anderson; S McIntosh; D F Harcherik; B A Shaywitz; D J Cohen
Journal:  Biol Psychiatry       Date:  1986-01       Impact factor: 13.382

8.  CSF monoamine metabolites in depression and schizophrenia.

Authors:  P A Berger; K F Faull; J Kilkowski; P J Anderson; H Kraemer; K L Davis; J D Barchas
Journal:  Am J Psychiatry       Date:  1980-02       Impact factor: 18.112

9.  CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective.

Authors:  J F Leckman; D J Cohen; B A Shaywitz; B K Caparulo; G R Heninger; M B Bowers
Journal:  Arch Gen Psychiatry       Date:  1980-06

10.  Determination of conjugated dopamine in cerebrospinal fluid from humans and non-human primates with high performance liquid chromatography using electrochemical detection.

Authors:  M Scheinin; T Seppala; M Koulu; M Linnoila
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.